Comparative Pharmacology
Head-to-head clinical analysis: NIMOTOP versus PLENDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIMOTOP versus PLENDIL.
NIMOTOP vs PLENDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation. It has a preferential effect on cerebral arteries, reducing the incidence of vasospasm following subarachnoid hemorrhage.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
60 mg orally every 4 hours for 21 days, initiated within 96 hours of subarachnoid hemorrhage. If unable to swallow, 0.5 mg/h continuous IV infusion via central line; increase to 1 mg/h after 2 hours if tolerated, continue for up to 21 days.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8–9 hours (range 3–12 hours) in adults, with clinical context of twice-daily dosing for continuous cerebral vasodilation in subarachnoid hemorrhage.
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Primarily hepatic metabolism; 50% excreted in urine as metabolites, 30% in feces via biliary elimination. Less than 1% excreted unchanged in urine.
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker